Business

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

CNBC · August 19, 2026 at 6:49 AM

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Read the full article on CNBC ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

More from CNBC

GoPro joins AI bonanza with pivot into data centers as shares skyrocket 38%

Stan Kroenke buys controlling stake in MLB's Los Angeles Angels

AI token prices are hitting new record lows

Penn. Gov. Shapiro says too many data center developers 'don't care about our communities'

More in Business

GoPro joins AI bonanza with pivot into data centers as shares skyrocket 38%

Global oil prices surge above $94 a barrel and settle at a 6-week high after the U.S. strikes Iran in Hormuz, and Trump threatens more action if Tehran retaliates

Stan Kroenke buys controlling stake in MLB's Los Angeles Angels

Trump Is Cutting Down Trees In D.C.—Here’s Why

The Iconic Huey Helicopter Is Disappearing. Enter The Agile Grey Wolf.

Sam Altman says he doesn’t like smart glasses: 'I find it very uncomfortable talking to people with a camera and a light’